Patient Demographics > Ethnicity > White
You are looking at 101 - 110 of 565 items
Search for other papers by Eimear Mary O’Donovan in
Google Scholar
PubMed
Search for other papers by Begona Sanchez-Lechuga in
Google Scholar
PubMed
Search for other papers by Emma Prehn in
Google Scholar
PubMed
Search for other papers by Maria Michelle Byrne in
Google Scholar
PubMed
Summary
The coexistence of autoimmune diabetes and maturity-onset diabetes (MODY) is rare. The absence of pancreatic autoantibodies is a key factor prompting MODY genetic testing. In this study, we report three cases of young-onset diabetes with progressive beta-cell dysfunction, strongly positive glutamic acid decarboxylase (GAD) antibodies, and genetic confirmation of pathogenic gene variants of HNF-1A, HNF-4A, and ABCC8-MODY. The first case is a woman diagnosed with HNF-1A-MODY diabetes more than 30 years after her diagnosis of adult-onset diabetes at 25 years. She required insulin after her fourth pregnancy. She became ketotic on oral hypoglycaemic agents (OHAs) and subsequently, her GAD antibodies tested positive. The second case is a woman diagnosed with diabetes at 17 years who was subsequently diagnosed with HNF-4A-MODY after many hypoglycaemic episodes on low-dose insulin. GAD antibodies were strongly positive. The last case is a man diagnosed with diabetes at 26 years who was well controlled on OHAs and required insulin years later due to sudden deterioration in glycaemic control. His ABCC8-MODY was diagnosed upon realisation of strong family history and his GAD antibodies tested positive. All subjects are now treated with insulin. Less than 1% of subjects with MODY have positive autoantibodies. These cases highlight individuals who may have two different types of diabetes simultaneously or consecutively. Deterioration of glycaemic control in subjects with MODY diabetes should highlight the need to look for the emergence of autoantibodies. At each clinic visit, one should update the family history as MODY was diagnosed in each case after the development of diabetes in their offspring.
Learning points
-
These cases highlight the rare coexistence of autoimmune diabetes and MODY.
-
Deterioration of glycaemic control in subjects with MODY diabetes should highlight the emergence of autoantibodies.
-
One should revise and update the family history as the diagnosis of MODY was made after the development of diabetes in offspring.
-
Understanding the spectrum of diabetes allows for precision medicine.
University of Adelaide, Adelaide, South Australia, Australia
Search for other papers by Annabelle G Hayes in
Google Scholar
PubMed
University of Adelaide, Adelaide, South Australia, Australia
Search for other papers by Mahesh M Umapathysivam in
Google Scholar
PubMed
University of Adelaide, Adelaide, South Australia, Australia
Search for other papers by David J Torpy in
Google Scholar
PubMed
Summary
Sulphonylureas are insulinotropic and are not only useful in patients with diabetes but also act in non-diabetic individuals where hypoglycaemia and hyperinsulinism mimic insulinoma. We present a 63-year-old man who presented with inadvertent sulphonylurea-induced life-threatening hypoglycaemia on two occasions, resulting in hazardous and invasive investigation. Biochemistry revealed endogenous hyperinsulinaemia, with elevated serum c-peptide and insulin concentrations during symptomatic hypoglycaemia, and plasma glucose of 1.7 mmol/L. There was no history of sulphonylurea use prompting anatomical insulinoma studies to locate an insulinoma. However, a routine plasma insulinoma screen-detected glimepiride. Directed history implicated a medication taken for erectile dysfunction prior to disturbed consciousness, with alcohol. The tablets, obtained online, were analysed by mass spectrometry and contained tadalafil and dapoxetine as advertised but also contained glimepiride.
Learning points
-
Symptomatic unexplained hypoglycaemia requires investigation with plasma glucose level, c-peptide, insulin level, pro-insulin, beta-hydroxybutyrate, and a sulphonylurea screen regardless of known exposure to sulphonylureas.
-
Consider contamination of alternative or undisclosed medication, including PDE-5 inhibitor erectile dysfunction drugs.
-
Concomitant alcohol may impair glycogenolysis and gluconeogenesis, exacerbating hypoglycaemia.
Search for other papers by N Viola in
Google Scholar
PubMed
Search for other papers by C Urbani in
Google Scholar
PubMed
Search for other papers by M Cosottini in
Google Scholar
PubMed
Search for other papers by A Abruzzese in
Google Scholar
PubMed
Search for other papers by L Manetti in
Google Scholar
PubMed
Search for other papers by G Cosentino in
Google Scholar
PubMed
Search for other papers by G Marconcini in
Google Scholar
PubMed
Search for other papers by C Marcocci in
Google Scholar
PubMed
Search for other papers by F Bogazzi in
Google Scholar
PubMed
Search for other papers by I Lupi in
Google Scholar
PubMed
Summary
Pituitary apoplexy (PA) is a medical emergency with complex diagnosis and management. In this study, we describe a case of PA in a 63-year-old male treated with oral anticoagulant therapy for atrial fibrillation. In the patient, PA manifested itself with asthenia and severe headache not responsive to common analgesics. Despite the finding of a pituitary mass through CT, and in anticipation of the endocrinological evaluation and pituitary MRI, the patient’s clinical condition worsened with an escalation of headache and asthenia associated with deterioration of the visual field and impairment of consciousness level. The emergency assessments revealed an adrenal failure, whereas MRI showed a haemorrhagic pituitary macroadenoma with compression of the optic chiasm. Intravenous fluids repletion and high-dose hydrocortisone were started with a rapid improvement of the patient’s health and visual field abnormalities. Hydrocortisone was gradually reduced to a replacement dose. During the follow-up, panhypopituitarism was documented, and replacement therapies with l-thyroxine and testosterone were introduced. Three months later, a pituitary MRI showed a 50% reduction in the pituitary adenoma volume.
Learning points
-
Pituitary apoplexy (PA) is a medical emergency that can result in haemodynamic instability and abnormalities in the level of consciousness.
-
The management of PA requires a multidisciplinary team that includes endocrinologists, ophthalmologists, neuro-radiologists, and neuro-surgeons.
-
Pituitary MRI with gadolinium is the diagnostic gold standard for PA.
-
PA therapy aims to improve general conditions and treat compression symptoms, especially visual field abnormalities.
-
Adrenocorticotrophic hormone deficiency is a common and severe complication of PA. Thus, all patients with PA must be promptly treated with injective synthetic glucocorticoids (e.g. hydrocortisone 100 mg) and i.v. saline.
-
PA must be taken into consideration in case of sudden headache in patients with a pituitary macroadenoma, especially if other risk factors are recognized.
Search for other papers by Sophie Bondje in
Google Scholar
PubMed
Search for other papers by Camilla Barnes in
Google Scholar
PubMed
Search for other papers by Felicity Kaplan in
Google Scholar
PubMed
Summary
Milk–alkali syndrome (MAS) is a triad of hypercalcaemia, metabolic alkalosis and renal insufficiency. In this study, we present a case of milk–alkali syndrome secondary to concurrent use of over-the-counter (OTC) calcium carbonate-containing antacid tablets (Rennie®) for dyspepsia and calcium carbonate with vitamin D3 (Adcal D3) for osteoporosis. A 72-year-old woman presented with a 2-day history of nausea, vomiting, epigastric pain, constipation, lethargy and mild delirium. Past medical history included osteoporosis treated with daily Adcal D3. Initial blood tests showed elevated serum-adjusted calcium of 3.77 mmol/L (normal range, 2.2–2.6) and creatinine of 292 µmol/L (45–84) from a baseline of 84. This was corrected with i.v. pamidronate and i.v. fluids. She developed asymptomatic hypocalcaemia and rebound hyperparathyroidism. Myeloma screen, vasculitis screen and serum angiotensin-converting enzyme (ACE) were normal, while the CT of the chest, abdomen and pelvis showed renal stones but no malignancy. A bone marrow biopsy showed no evidence of malignancy. Once the delirium resolved, we established that prior to admission, she had been excessively self-medicating with over-the-counter antacids (Rennie®) as required for epigastric pain. The increasing use of calcium preparations for the management of osteoporosis in addition to easily available OTC dyspepsia preparations has made MAS the third most common cause of hypercalcaemia hospitalisations. Educating patients and healthcare professionals on the risks associated with these seemingly safe medications is required. Appropriate warning labels on both calcium preparations used in the management of osteoporosis and OTC calcium-containing preparations would prevent further similar cases and unnecessary morbidity and hospital admission.
Learning points
What is known?
-
An association between high-dose calcium supplementation and hypercalcaemia crisis has been seen in case studies.
-
After as little as 1 week of excessive calcium carbonate ingestion, patients can present with symptomatic hypercalcemia, acute renal failure and metabolic alkalosis (1).
-
Women aged 50 and younger need 1 g of calcium per day, while aged 51 and older need 1.2 g (1).
-
Although the amount of calcium required for MAS is generally thought to be more than 4 g per day, there have been reports at intakes as low as 1.0–1.5 g per day in pre-existing risk factors including renal impairment (2).
What this study adds?
-
The danger of excessive ingestion of antacid is not adequately highlighted to prescribers and patients.
-
Appropriate warning labels on OTC calcium-containing preparations could prevent unnecessary morbidity and hospital admission.
Search for other papers by Leevi A Toivonen in
Google Scholar
PubMed
Search for other papers by Marko H Neva in
Google Scholar
PubMed
Search for other papers by Thanos Sioris in
Google Scholar
PubMed
Search for other papers by Pia Isomäki in
Google Scholar
PubMed
Search for other papers by Saara Metso in
Google Scholar
PubMed
Summary
Gorham–Stout disease (GSD) is a rare bone disease characterized by massive osteolysis and lymphatic proliferation. The origin of the condition is unknown, and no established treatment protocol exists. Massive pleural effusion is a frequent complication of GSD in the thoracic region. We present the case of a 23-year-old male with thoracic GSD, subsequent paraparesis, and life-threatening pleural effusion. The patient was managed by a multidisciplinary team with a good recovery. The pleural effusion was successfully treated with a pleuro-peritoneal shunt. This is the first report of the use of this mini-invasive technique in the management of pleural effusion related to GSD. Further, we present the potential role of interleukin-6 and bone resorption markers in the measurement of the disease activity.
Learning points
-
Multidisciplinary approach is important in the management of rare and severe disorders such as Gorham-Stout disease.
-
Pleuro-peritoneal shunting is a valuable option in the treatment of pleural effusion related to GSD.
-
Interleukin-6 and bone resorption markers appear useful in measuring the disease activity of GSD.
Search for other papers by Melanie Nana in
Google Scholar
PubMed
Search for other papers by Catherine Nelson-Piercy in
Google Scholar
PubMed
Summary
COVID-19 is associated with severe disease in pregnancy. Complications of the disease, or simultaneous diagnoses, may be missed if clinicians do not retain a large differential diagnosis when assessing such women. Starvation ketoacidosis is one such diagnosis which may complicate the disease and should not be missed. A 37-year-old woman, 33 weeks’ gestation presented with breathlessness. Clinical history, examination and investigations supported a diagnosis of starvation ketosis of pregnancy complicating COVID-19 pneumonitis. Prompt correction of the metabolic disturbance resulted in resolution, and preterm delivery was avoided at this time. Early recognition and prompt management of starvation ketosis of pregnancy in women with COVID-19 are important in reducing maternal and neonatal morbidity and mortality. Preterm delivery may be avoided with prompt resolution of the metabolic disturbance. Clinicians should keep a wide differential diagnosis when assessing women with breathlessness. A multidisciplinary team (MDT) approach is required to facilitate optimal care.
Learning points
-
Clinicians should maintain a wide differential when assessing women who are unwell with COVID-19 in pregnancy.
-
Complications such as starvation ketoacidosis are rare but life-threatening.
-
An awareness of such complications facilitates early identification of the condition, and involvement of appropriate specialists who can initiate optimal and timely management.
-
In the context of pregnancy, where ketoacidosis poses a threat to the mother or baby, prompt management and resolution may avoid preterm delivery.
-
Conditions that may increase the risk of developing starvation ketoacidosis include pregnancy, medication use such as corticosteroids or tocolytic therapies, previous gastric surgery, intercurrent illness and pregnancy-related conditions that might contribute towards a degree of chronic starvation.
-
Multidisciplinary input supports the delivery of best practice and care for the patients.
Search for other papers by Naomi Szwarcbard in
Google Scholar
PubMed
Search for other papers by Anna Davis in
Google Scholar
PubMed
Department of Medicine, Monash University, Melbourne, Australia
Search for other papers by Leon A Bach in
Google Scholar
PubMed
Department of Medicine, Monash University, Melbourne, Australia
Search for other papers by Kathryn Hackman in
Google Scholar
PubMed
Summary
Adrenal gland haemorrhage is an uncommon, yet likely under-diagnosed complication of high-impact trauma, such as motor vehicle accidents (MVA). It usually occurs with multi-trauma and is associated with additional injuries to the ribs, liver, kidney, spleen and vertebrae. Trauma cases with resultant adrenal gland injury have higher mortality rates. Primary adrenal insufficiency as a result of bilateral adrenal haemorrhage is potentially fatal. We report three cases of life-threatening adrenal insufficiency following adrenal injuries sustained in MVA’s. Case 1 was a 60-year-old-male who presented with acute haemodynamic instability on admission. Case 2 was an 88-year-old female on anticoagulation for atrial fibrillation, who developed haemodynamic instability 10 days into her admission. Case 3 was a 46-year-old male who developed hyponatraemia 2 weeks post-MVA. All were commenced on stress dose hydrocortisone replacement with improvement in clinical status. Only case 1 has had complete adrenal axis recovery, whereas the other patients remain on maintenance hydrocortisone replacement. Our cases demonstrate acute and subacute presentations of adrenal insufficiency following traumatic bilateral adrenal haemorrhages and highlight the importance of assessing adrenal morphology and function in any trauma patient with haemodynamic instability or hyponatraemia.
Learning points
-
Adrenal gland haemorrhage is an under-diagnosed consequence of high-impact trauma.
-
Trauma patients with adrenal haemorrhage have a significantly increased mortality risk.
-
Bilateral adrenal gland haemorrhage can result in life-threatening adrenal insufficiency requiring urgent glucocorticoid replacement.
-
Biochemical assessment of the adrenocortical axis should be considered in all patients presenting with high-impact trauma following motor vehicle accidents.
-
Given the potential for delayed presentation, any patients with new haemodynamic instability should have repeat biochemistry and/or imaging performed, even if initial adrenal imaging and investigations were normal.
Search for other papers by Kushalee Poornima Jayawickreme in
Google Scholar
PubMed
Search for other papers by Dimuthu T Muthukuda in
Google Scholar
PubMed
Search for other papers by Chithranga Kariyawasam in
Google Scholar
PubMed
Search for other papers by Lalitha Piyarisi in
Google Scholar
PubMed
Search for other papers by Buddhi A Abeywickrama in
Google Scholar
PubMed
Summary
Treatment of insulinoma can be challenging, while surgical resection is considered the first line. When surgery is contraindicated or is refused, minimally invasive procedures such as selective arterial embolization, local ablative techniques including alcohol ablation, radiofrequency ablation and microwave ablation are being used of late. The world’s first microwave ablation of insulinoma was performed in 2015, after which there have been only a handful of reported cases. A 78-year-old female presented with painful swelling of the left lower limb. She was drowsy and was previously misdiagnosed as epilepsy when she had similar episodes since 2 years ago. She had hypoglycaemia with high serum insulin and C-peptide, and mildly high adjusted calcium, serum prolactin. MRI did not show pituitary adenoma. Lower limb venous duplex scan showed left lower limb deep vein thrombosis for which she was treated with anticoagulation. CT of the abdomen showed a tumour measuring 1.8 cm, located in the antero-superior aspect of the body of the pancreas, with the superior surface being abutted by the splenic artery and the inferior surface being 3 mm above the pancreatic duct, suggestive of an insulinoma. Selective transcatheter arterial embolization of the pancreatic tumour was attempted but was abandoned due to multiple small feeding arteries. Microwave ablation of the tumour was performed successfully. Since there was a possibility of the ablation being compromised due to the heat sink at the splenic artery, 2 mL of 99% alcohol was injected into the rim of the tumour near the artery. She was subsequently normoglycaemic. She defaulted follow up for repeat imaging of pancreas and screening for MEN1 syndrome due to the impact of the COVID-19 pandemic. Minimally invasive procedures are preferred over surgery in selected patients with insulinoma, out of which microwave ablation could be preferentially recommended due to its efficacy and minimal complications. We report the first case of MWA performed in combination with AA in successfully treating insulinoma to our knowledge. This is also the first reported case of DVT associated with isolated insulinoma prior to intervention, though it is rarely reported in MEN1 syndrome.
Learning points
-
Novel therapeutic minimally invasive procedures are successful in treating selected cases of insulinoma.
-
Microwave ablation could be recommended preferentially over selective trans-arterial embolization, and radiofrequency ablation in treating insulinoma due to its efficacy and minimal complications.
-
We report the first case of microwave ablation performed in combination with alcohol ablation in successfully treating insulinoma to our knowledge.
Saint Louis University School of Medicine, St. Louis, Missouri, USA
Search for other papers by Megha Verma in
Google Scholar
PubMed
Search for other papers by Stephen I Stone in
Google Scholar
PubMed
Summary
We identified an adolescent young woman with new-onset diabetes. Due to suspicious family history, she underwent genetic testing for common monogenic diabetes (MODY) genes. We discovered that she and her father carry a novel variant of uncertain significance in the HNF1A gene. She was successfully transitioned from insulin to a sulfonylurea with excellent glycemic control. Based on her family history and successful response to sulfonylurea, we propose that this is a novel pathogenic variant in HNF1A. This case highlights the utility of genetic testing for MODY, which has the potential to help affected patients control their diabetes without insulin.
Learning points
-
HNF1A mutations are a common cause of monogenic diabetes in patients presenting with early-onset diabetes and significant family history.
-
Genetic testing in suspected patients allows for the identification of mutations causing monogenic diabetes.
-
First-degree relatives of the affected individual should be considered for genetic testing.
-
The use of sulfonylurea agents in patients with HNF1A-MODY can reduce dependence on insulin therapy and provide successful glycemic control.
Search for other papers by N Ayub in
Google Scholar
PubMed
Search for other papers by A J A T Braat in
Google Scholar
PubMed
Search for other papers by H J L M Timmers in
Google Scholar
PubMed
Search for other papers by M G E H Lam in
Google Scholar
PubMed
Search for other papers by R S van Leeuwaarde in
Google Scholar
PubMed
Summary
Von Hippel–Lindau’s disease (VHL) is a hereditary tumor syndrome characterized by its prototype lesions, hemangioblastomas, and renal cell carcinomas. Treatment for renal cell carcinomas can ultimately result in long-term dialysis. Pancreatic neuroendocrine tumors (pNET) can also occur in the course of the disease. Currently, peptide receptor radionuclide therapy (PRRT) is the standard treatment for progressive neuroendocrine tumors. However, little is known about treatment with PRRT in patients on dialysis, an infrequent presentation in patients with VHL. We present a 72-year-old man with VHL on hemodialysis and a progressive pNET. He received four cycles of PRRT with a reduced dose. Only mild thrombopenia was seen during treatments. The patient died 9 months after the last PRRT because of acute bleeding in a hemangioblastoma. Hemodialysis is not a limiting factor for PRRT treatment and it should be considered as it seems a safe short-term treatment option for this specific group.
Learning points
-
Von Hippel–Lindau disease (VHL) is a complex disease in which former interventions can limit optimal treatment for following VHL-related tumors later in life.
-
Metastasized pancreatic neuroendocrine tumors occur as part of VHL disease.
-
Peptide receptor radionuclide therapy seems a safe short-term treatment option in patients on hemodialysis.